Baillie Gifford's position in Genmab is currently worth $329. That's 0.00% of their equity portfolio (255th largest holding). The first Genmab trade was made in Q4 2023. Since then Baillie Gifford bought shares one more times and sold shares on two occasions. The investor's estimated purchase price is $373, resulting in a loss of 12%.